These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 16012905)

  • 1. MCC-555 (Mitsubishi-Tokyo Pharmaceuticals).
    Velussi M
    IDrugs; 2001 May; 4(5):586-9. PubMed ID: 16012905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties.
    Reginato MJ; Bailey ST; Krakow SL; Minami C; Ishii S; Tanaka H; Lazar MA
    J Biol Chem; 1998 Dec; 273(49):32679-84. PubMed ID: 9830009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
    Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
    Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
    Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
    Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists.
    Liu Q; Zhang YY; Lu HL; Li QY; Zhou CH; Wang MW
    Acta Pharmacol Sin; 2007 Dec; 28(12):2033-9. PubMed ID: 18031620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
    Geese WJ; Achanzar W; Rubin C; Hariharan N; Cheng P; Tomlinson L; Ordway N; Dracopoli NC; Delmonte T; Hui L; Krishnan B; Cosma G; Ranade K
    Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects.
    Carmona MC; Louche K; Lefebvre B; Pilon A; Hennuyer N; Audinot-Bouchez V; Fievet C; Torpier G; Formstecher P; Renard P; Lefebvre P; Dacquet C; Staels B; Casteilla L; Pénicaud L;
    Diabetes; 2007 Nov; 56(11):2797-808. PubMed ID: 17704298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loxiglumide Rotta research.
    Katschinski M
    IDrugs; 2002 May; 5(5):469-74. PubMed ID: 15570466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
    Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
    Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
    Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M
    Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INT-131, a PPARgamma agonist for the treatment of type 2 diabetes.
    Kintscher U; Goebel M
    Curr Opin Investig Drugs; 2009 Apr; 10(4):381-7. PubMed ID: 19337960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
    Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS
    J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.